Form D · Biotechnology

Dare Bioscience, Inc.

San Diego, CA · CIK 0001401914

Offering snapshot reported Aug 20, 2026 · SEC filing

Reported sold
$12.4M
Offering amount: $12.4M
Investors reported
12
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Aug 17, 2026
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Aug 20, 2026Initial$12,375,054No comparison12SEC filing
Nov 22, 2024Initial$0No comparison1SEC filing
Dec 26, 2023Initial$1,733,500No comparison1SEC filing
Sep 7, 2021Amendment$3,544,992$1,175,000vs Dec 6, 201928SEC filing
Dec 6, 2019Initial$2,369,992No comparison28SEC filing
Jul 28, 2017Initial$20,691,388No comparison18SEC filing
Oct 17, 2016Initial$1No comparison1SEC filing
Dec 14, 2012Initial$13,000,000No comparison16SEC filing
Dec 15, 2011Initial$15,000,098No comparison19SEC filing
Nov 19, 2010Initial$16,499,994No comparison17SEC filing
Oct 13, 2010Initial$1,499,999No comparison15SEC filing
Jun 9, 2010Initial$5,000,000No comparison13SEC filing
Jul 27, 2009Initial$10,000,000No comparison13SEC filing
Jan 22, 2008PaperNot reportedNo comparisonNot reportedSEC filing
May 29, 2007PaperNot reportedNo comparisonNot reportedSEC filing

Offering details

Securities
Option to acquire, Security to be acquired
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-594815
The total offering amount reflects proceeds if all warrants, consisting of 8,759,162 and 175,183 shares of common stock exercisable at $1.37 and $2.1235 per share, respectively, are exercised for cash. No warrants have been exercised as of this filing.

Sales compensation recipients

Scroll to see all columns →

RecipientCRDAssociated broker-dealer
Ladenburg Thalmann & Co. Inc.000000505Ladenburg Thalmann & Co. Inc. · CRD 000000505

Source: Form D, filed Aug 20, 2026. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No matching detailed fund disclosure was found in the latest imported ADV filings. This does not establish that the issuer has no adviser.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Stuart A. Arbuckle Director
Gregg Beloff Executive
Cheryl R. Blanchard Director
Alejandra V. Carvajal Executive
Alan L. Crane Director
David P. De Magistris Executive
Oliver Fetzer Director, Executive
Paul A. Friedman Director
Edward Garmey Executive
Alexandra Glucksmann Executive
Jessica D. Grossman Director
Christopher D.T. Guiffre Director, Executive
Steven E. Hall Director
Mar Dee Haring Layton Executive
Roger L. Hawley Director
Sabrina Martucci Johnson Director, Executive
Susan L. Kelley Director
Robert Langer Director
Gregory W. Matz Director
Terry Mc Guire Director
William T. Mc Kee Director
Sophia N. Ononye Onyia Director
David R. Parkinson Director
Robert Paull Director
William H. Rastetter Director
Karen Roberts Executive
Bryan E. Roberts Director
John Ryan Executive
Ram Sasisekharan Director
Adrian Senderowicz Executive
Jean Silveri Executive
Robin J. Steele Director
Robert Tepper Director
David R. Walt Director
Lisa Walters Hoffert Executive

Issuer details

Industry: Biotechnology (See others in industry)

Address:
3655 Nobel Drive Suite 260
San Diego, CA, 92122
Phone: 858-926-7655